A novel non-invasive diagnostic imaging technique of metastatic cancer using plasminogen activator inhibitor type 2.

使用 2 型纤溶酶原激活剂抑制剂的转移性癌症的新型非侵入性诊断成像技术。

• 批准号: nhmrc : 354125
• 负责人: A/Pr Martin Carolan
• 金额: $ 12.52万
• 依托单位: University of Wollongong
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Development Grants
• 财政年份: 2005
• 资助国家: 澳大利亚
• 起止时间: 2005-01-01 至 2005-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/novel-non-invasive-type-2/101294
• 关键词: novel; non; invasive; diagnostic; imaging

This project aims to develop a non-invasive tumour diagnostic imaging agent based on a non-toxic protein (PAI2) that we know specifically identifies a critical marker of malignancy. PAI2 will be labelled with commonly used imaging radioisotopes. This novel imaging technique has important potential clinical uses including, determination of the most appropriate treatment for individual patients, assessing the success of such treatments, and a novel non-invasive prognostic indicator of malignancy.

该项目旨在开发一种基于无毒蛋白（PAI2）的非侵入性肿瘤诊断成像剂，我们知道这种蛋白可以特异性识别恶性肿瘤的关键标志物。 PAI2 将用常用的成像放射性同位素进行标记。这种新颖的成像技术具有重要的潜在临床用途，包括确定个体患者最合适的治疗、评估此类治疗的成功以及一种新颖的非侵入性恶性肿瘤预后指标。